AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9655734
Drug: Antioxidant vitamin
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamin supplementation (75 mg vitamin E, 650 mg vitamin C, 15 mg beta carotene)
Trial: 7649323
Drug: Adjuvant alpha‐interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant alpha‐interferon treatment (once a week for 8 weeks)
Trial: 7649323
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant interferon treatment (control group)
Trial: 2501765
Drug: Insulin bolus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin bolus (n = 24)
Trial: 2501765
Drug: No insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No insulin bolus (n = 32)
Trial: 588388
Drug: Pentolinium tartrate
RxNorm normalized name: pentolinium tartrate
DrugBank: Pentolinium (DB01090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentolinium tartrate (Ansolysen) in doses of 10-15 mg
Trial: 29688121
Drug: RV3-BB vaccine
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RV3-BB vaccine (three doses, first dose at 0-5 days after birth)
Trial: 29688121
Drug: RV3-BB vaccine
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RV3-BB vaccine (three doses, first dose at about 8 weeks after birth)
Trial: 28729014
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium fluorescein
Trial: 21428727
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 or 50 mg, depending on renal function)
Trial: 26041585
Drug: Glimepiride (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (titrated doses)
Trial: 18328440
Drug: Commercial MCT‐enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial MCT‐enriched dietary supplements
Trial: 15902724
Drug: Fuzhenghuayu capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzhenghuayu capsule
Trial: 15902724
Drug: Heluoshugan capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heluoshugan capsule
Trial: 14630567
Drug: CDP860 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP860 (25 mg/kg)
Trial: 11550107
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (n = 2882)
Trial: 1511192
Drug: Dry group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry group (fluid administration: 50, 60, 70, 80, 90, 100 and 120 ml/kg/day during the first week and 150 ml/kg/day until aged four weeks)
Trial: 1511192
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (fluid administration: 80, 100, 120 and 150 ml/kg/day during the first week and 200 ml/kg afterwards)
Trial: 30160627
Drug: LOW (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOW (9 weekly sets, 1 session per week)
Trial: 30160627
Drug: MOD (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOD (18 weekly sets, 2 sessions per week)
Trial: 30160627
Drug: HIGH (27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGH (27 weekly sets, 2 sessions per week)
Trial: 23547239
Drug: Biomarker combinations
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker combinations centered on insulin‐like growth factor acid labile subunit
Trial: 20970976
Drug: MK-0633 100
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0633 100 mg
Trial: 18713501
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive therapy (IPT) for 6 months, offered to 568 subjects, with 565 accepting.
Trial: 18713501
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive therapy (IPT) with counseling and monthly follow-up.
Trial: 16540519
Drug: 3.5 ml
RxNorm normalized name: ethanol 3.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 ml of alcohol gel
Trial: 16540519
Drug: 1.75 ml
RxNorm normalized name: ALCOHOL 1.75 mL TOPICAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.75 ml of alcohol gel
Trial: 14571789
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with interferon alfa-2a (4.5 MU thrice weekly) and amantadine (200 mg daily)
Trial: 14571789
Drug: Interferon therapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon therapy alone (4.5 MU thrice weekly)
Trial: 14571789
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with interferon alfa-2a and amantadine
Trial: 14571789
Drug: Interferon therapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon therapy alone
Trial: 10736080
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (M)
Trial: 10736080
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine with butorphanol (M+B)
Trial: 8726243
Drug: Pravastatin 5
RxNorm normalized name: pravastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 5 mg/d
Trial: 3034623
Drug: Calcium entry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium entry blockers PY 108‐068 (PY)
Trial: 3034623
Drug: Calcium entry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium entry blockers PN 200‐110 (PN)
Trial: 25794636
Drug: Clinical Case
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical Case Management with Problem-Solving Therapy (CM-PST)
Trial: 26576808
Drug: Meridian balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meridian balanced method electroacupuncture (BMEA) + Traditional Chinese Medicine Health Consultation (TCM HC)
Trial: 26576808
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine Health Consultation (TCM HC)
Trial: 12685514
Drug: Trandolapril (Tra)
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trandolapril (Tra) 2 mg
Trial: 12685514
Drug: Quinapril (Qui)
DrugBank: Quinapril (DB00881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinapril (Qui) 20 mg
Trial: 10073329
Drug: OROS oxybutynin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS oxybutynin chloride 5 mg once daily for 4 days
Trial: 10073329
Drug: Immediate-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release oxybutynin 5 mg every 8 hours for 4 days
Trial: 8839195
Drug: Ultra-high-dose streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-high-dose streptokinase
Trial: 8839195
Drug: Conventional-dose streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose streptokinase
Trial: 14621759
Drug: CMV-Polyglobulin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV-Polyglobulin (2 ml/kg body weight)
Trial: 14621759
Drug: Intraglobin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraglobin (15 g)
Trial: 3935486
Drug: 19NT-hexoxyphenylpropionate (19NT-HPP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19NT-hexoxyphenylpropionate (19NT-HPP), 200 mg/week intramuscularly for 7 weeks
Trial: 29539274
Drug: Oral regimen
RxNorm normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral regimen (fluconazole 1200 mg/day plus flucytosine 100 mg/kg/day for 2 weeks)
Trial: 29539274
Drug: 1-week amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-week amphotericin B (1 mg/kg/day)
Trial: 29539274
Drug: 2-week amphotericin
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week amphotericin B (1 mg/kg/day)
Trial: 29539274
Drug: Flucytosine as
RxNorm normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flucytosine as partner drug with amphotericin B
Trial: 30640987
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal fumigation combined with leflunomide (20 mg) and prednisone (15 mg) once per day for 6 months
Trial: 30640987
Drug: Western drugs
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western drugs (leflunomide and prednisone)
Trial: 25007725
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous (IV) and topical application of tranexamic acid (TXA): 1.5 g topical TXA + 1.5 g IV-TXA
Trial: 25007725
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (IV-TXA): 3 g
Trial: 22505603
Drug: Buprenorphine 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 180 µg/m(2) with carprofen 4 mg/kg
Trial: 22505603
Drug: Buprenorphine 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 180 µg/m(2) with meloxicam 0.3 mg/kg
Trial: 22505603
Drug: Butorphanol 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 6 mg/m(2) with carprofen 4 mg/kg
Trial: 22505603
Drug: Butorphanol 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 6 mg/m(2) with meloxicam 0.3 mg/kg
Trial: 16041635
Drug: Conventional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intravenous fluid management
Trial: 7751709
Drug: Pentoxifylline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (10 mg/kg/day by continuous intravenous infusion)
Trial: 30350477
Drug: Dasiglucagon 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasiglucagon 0.03 mg
Trial: 30350477
Drug: Dasiglucagon 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasiglucagon 0.08 mg
Trial: 30350477
Drug: Dasiglucagon 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasiglucagon 0.2 mg
Trial: 30350477
Drug: Commercial glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Commercial glucagon (Eli Lilly) 0.03 mg
Trial: 30350477
Drug: Commercial glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Commercial glucagon (Eli Lilly) 0.08 mg
Trial: 30350477
Drug: Commercial glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Commercial glucagon (Eli Lilly) 0.2 mg
Trial: 30350477
Drug: Dasiglucagon 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasiglucagon 0.03 mg in hypoglycaemia
Trial: 30350477
Drug: Dasiglucagon 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasiglucagon 0.08 mg in hypoglycaemia
Trial: 30350477
Drug: Dasiglucagon (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasiglucagon (all doses)
Trial: 29223585
Drug: Concentrated beetroot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated beetroot juice drink (BR; 55 mL)
Trial: 29223585
Drug: Non-concentrated beetroot
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-concentrated beetroot juice drink (BL; 456 mL)
Trial: 29223585
Drug: Solid beetroot
RxNorm normalized name: Corydalis solida whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid beetroot flapjack (BF; 60 g)
Trial: 29223585
Drug: Control drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drink (CON; 70 mL deionised water)
Trial: 17286243
Drug: Montelukast (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (0 - 0 - 10 mg)
Trial: 16119601
Drug: Propofol 6
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 6 mg kg(‐1) h(‐1) in oxygen 33% and air
Trial: 2179283
Drug: Metoprolol CR/ZOK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/ZOK 50 mg once daily for 4 weeks
Trial: 2179283
Drug: Metoprolol CR/ZOK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/ZOK 50 mg daily
Trial: 696981
Drug: Diazepam (Valium)
RxNorm normalized name: diazepam Oral Tablet [Valium]
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam (Valium) 0.3 mg/kg
Trial: 25798748
Drug: Continuous urinary
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous urinary catheterization (CC)
Trial: 21145839
Drug: BI201335 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI201335 20 mg once-daily for 14 days
Trial: 21145839
Drug: BI201335 48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI201335 48 mg once-daily for 14 days
Trial: 21145839
Drug: BI201335 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI201335 120 mg once-daily for 14 days
Trial: 21145839
Drug: BI201335 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI201335 240 mg once-daily for 14 days
Trial: 21145839
Drug: BI201335 48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI201335 48 mg once-daily with PegIFN/RBV for 28 days
Trial: 21145839
Drug: BI201335 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI201335 120 mg once-daily with PegIFN/RBV for 28 days
Trial: 21145839
Drug: BI201335 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI201335 240 mg once-daily with PegIFN/RBV for 28 days
Trial: 16770028
Drug: Topical Mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Mitomycin C (0.01%)
Trial: 15511682
Drug: Zonisamide (ZNS)
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide (ZNS) monotherapy initiated at 2mg/kg, increased to maintenance dosage of 8.0 mg/kg (mean, 7.97 +/- 0.55 mg/kg)
Trial: 15511682
Drug: Zonisamide (ZNS)
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide (ZNS) monotherapy
Trial: 8252111
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine oestrogens, 0.625 mg daily, with cyclical oral dl-norgestrel, 0.15 mg daily
Trial: 8252111
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta-oestradiol, 0.05 mg daily, with cyclical transdermal norethisterone acetate, 0.25 mg daily
Trial: 3608343
Drug: Ketoprofen 100mg
RxNorm normalized name: KETOPROFEN 100MG CAP,SA
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100mg administered at 07.00 hours
Trial: 3608343
Drug: Ketoprofen 100mg
RxNorm normalized name: KETOPROFEN 100MG CAP,SA
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100mg administered at 13.00 hours
Trial: 3608343
Drug: Ketoprofen 100mg
RxNorm normalized name: KETOPROFEN 100MG CAP,SA
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100mg administered at 19.00 hours
Trial: 3608343
Drug: Ketoprofen 100mg
RxNorm normalized name: KETOPROFEN 100MG CAP,SA
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100mg administered at 01.00 hours
Trial: 29579503
Drug: Daily PIVO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily PIVO blood collections
Trial: 26278513
Drug: Pre-filled pen
RxNorm normalized name: Kevzara Pre-filled Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled pen (75 mg and 150 mg doses)
Trial: 26278513
Drug: Pre-filled syringe
RxNorm normalized name: Eylea Pre-filled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled syringe (75 mg and 150 mg doses)
Trial: 12957251
Drug: RCT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT plus amifostine (300 mg/m² daily i.v. infusion)
Trial: 11235460
Drug: Warmed arthroscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed arthroscopic irrigation solution
Trial: 11235460
Drug: Room-temperature irrigation
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room-temperature irrigation solution
Trial: 8878577
Drug: Clarithromycin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (8 to 12 mg/kg)
Trial: 8878577
Drug: Roxithromycin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin (8 to 12 mg/kg)
Trial: 1521653
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) and human menopausal gonadotropins (hMG)
Trial: 6380347
Drug: Pentoxifylline (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (600 mg by mouth daily, increased to 1200 mg daily after one month)
Trial: 30612112
Drug: Metformin, 500
RxNorm normalized name: Repaglinide-Metformin, 500 mg-1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin, 500 mg, three times/day during 4 months + lifestyle management
Trial: 30062577
Drug: Psilocybin (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (10, 20, and 30 mg/70 kg)
Trial: 30062577
Drug: Dextromethorphan (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (400 mg/70 kg)
Trial: 24206010
Drug: Cold therapy
RxNorm normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold therapy (cold pack applied over abdomen and back for 10 minutes every 30 minutes during first phase of labour; cold pack over perineum for 5 minutes every 15 minutes during second phase)
Trial: 20337606
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab in combination with photodynamic therapy (COMB group)
Trial: 17242095
Drug: Eritoran 2
RxNorm normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eritoran 2 mg
Trial: 11929196
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 mixed plant oil capsules for 2 months)
Trial: 10403065
Drug: Rizatriptan (5HT1B/1D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan (5HT1B/1D receptor agonist)
Trial: 10403065
Drug: Usual migraine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual migraine therapy
Trial: 7726322
Drug: Inositol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inositol (12 g/day)
Trial: 2383198
Drug: Prostaglandin F2
RxNorm normalized name: Prostaglandin F2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F2 alpha‐isopropylester (PGF2 alpha‐IE) 0.5 microgram, twice daily for 1 week
Trial: 19887475
Drug: Vorinostat (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (800 mg)
Trial: 11433046
Drug: Educational outreach
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational outreach intervention for families and physicians, including 2 meetings with a physician peer leader and feedback on previous prescribing rates. Parents received a CDC brochure on antibiotic use.
Trial: 7996376
Drug: Pentoxifylline (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1600 mg/day)
Trial: 3054429
Drug: Glycerol-insulin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol-insulin treatment
Trial: 8147960
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin treatment
Trial: 31129983
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) for nightmares delivered over 4 weeks in addition to treatment as usual (TAU)
Trial: 31129983
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) for nightmares
Trial: 25933201
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of rhFGF-2/HA in the intrabony defect
Trial: 10789602
Drug: sustained-release nifedipine
RxNorm normalized name: nifedipine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained-release nifedipine
Trial: 8450166
Drug: Clentiazem 40
RxNorm normalized name: diltiazem hydrochloride Extended Release Oral Capsule [Kentiazem]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clentiazem 40 mg/day
Trial: 8450166
Drug: Clentiazem 80
RxNorm normalized name: diltiazem hydrochloride Extended Release Oral Capsule [Kentiazem]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clentiazem 80 mg/day